BioMarin Pharmaceutical (NASDAQ:BMRN) Announces Earnings Results

BioMarin Pharmaceutical (NASDAQ:BMRN) released its earnings results on Monday. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.28, FiscalAI reports. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.02 billion. BioMarin Pharmaceutical had a negative net margin of 0.52% and a positive return on equity of 5.59%. The business’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.12 earnings per share.

Here are the key takeaways from BioMarin Pharmaceutical’s conference call:

• Third-quarter revenue rose 32% year over year to more than $1 billion, driven by broad-based demand across BioMarin’s portfolio. Metabolic conditions revenue increased 44%, while VOXZOGO patient counts grew 17% globally.
• GALAFOLD revenue increased 10% to $152 million and POMBILITI + OPFOLDA revenue rose 58% to $49 million, with patient counts up approximately 13% and 69%, respectively. Management expects Pompe revenue benefits from competitor supply constraints to build into 2027 and beyond, although the durability of those gains remains uncertain.
• BioMarin lowered 2026 guidance to revenue of $3.8 billion-$3.9 billion and non-GAAP diluted EPS of $2.80-$3.10. The revision reflects roughly $70 million of customer orders potentially moving from late 2026 into early 2027, along with disruption and liquidity pressures related to the Middle East conflict.
• VOXZOGO’s potential expansion into hypochondroplasia received a May 30, 2027 PDUFA date, creating a potential new growth opportunity in an estimated 14,000-child global market. Management expects VOXZOGO revenue to continue growing in 2027 despite competitive pressures and order-timing uncertainty.
• BioMarin added four pipeline programs in 2026, including BMN 450 for potentially subcutaneous, mutation-agnostic Fabry treatment and BMN 440 as a potential oral therapy for hypophosphatasia. Amicus integration is ahead of schedule, with management now expecting the deal to be accretive within nine months and tracking toward possible 2026 calendar-year accretion.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock opened at $55.66 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The business has a fifty day moving average of $60.24 and a two-hundred day moving average of $58.45. BioMarin Pharmaceutical has a one year low of $49.26 and a one year high of $70.98. The company has a market cap of $10.77 billion, a P/E ratio of -556.60, a price-to-earnings-growth ratio of 0.63 and a beta of 0.21.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Wall Street Zen cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday. Jefferies Financial Group raised their target price on BioMarin Pharmaceutical from $104.00 to $105.00 and gave the stock a “buy” rating in a research report on Monday, August 31st. Citigroup boosted their price objective on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. HC Wainwright reiterated a “neutral” rating and set a $60.00 price target on shares of BioMarin Pharmaceutical in a research note on Tuesday. Finally, Morgan Stanley reduced their target price on BioMarin Pharmaceutical from $122.00 to $119.00 and set an “overweight” rating for the company in a report on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $87.96.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Third-quarter revenue rose 32% year over year to about $1.025 billion, in line with expectations, while earnings of $0.23 per share beat estimates for a loss. Growth was led by metabolic and skeletal-condition products. BioMarin Q3 results
• Positive Sentiment: BioMarin added an investigational Fabry asset to its clinical pipeline and reported a May 30, 2027, FDA action date for VOXZOGO in hypochondroplasia. These developments may bolster longer-term growth prospects. Analyst view of BioMarin’s growth potential
• Neutral Sentiment: Analyst views were mixed: Morgan Stanley maintained an Overweight rating despite reducing its target to $119, while RBC lowered its target to $60 and kept Sector Perform; HC Wainwright reiterated Neutral at $60. Morgan Stanley rating information
• Neutral Sentiment: Call-option trading was unusually active, with volume 228% above its typical level. This signals increased trading interest but does not establish a clear direction for the shares.
• Negative Sentiment: BioMarin cut 2026 guidance to $2.80–$3.10 in earnings per share and $3.8–$3.9 billion in revenue, versus consensus of $3.32 and $3.9 billion, respectively. The company cited order-timing uncertainty and charges tied to two acquired research programs, making the weaker outlook a likely near-term overhang despite the quarterly beat. 2026 guidance update

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.